Loading...
•
Dec 31, 2019
IRadimed Q4 2019 Earnings Report
Reported revenue increase and record high orders, operationally accomplished with resolving FDA warning letter and regaining CE Mark for patient monitor.
Key Takeaways
iRadimed Corporation announced financial results for Q4 2019, with revenue increasing over 30% compared to Q4 2018. The company reported net income of $3.2 million, or $0.26 per diluted share, compared to $1.7 million, or $0.14 per diluted share for the fourth quarter 2018.
Revenue for the fourth quarter increased over 30% from the fourth quarter last year.
The fourth quarter marked the first period with orders exceeding $10 million.
Resolved the FDA warning letter and regained the CE Mark for patient monitor.
Non-GAAP earnings per diluted share was $0.30, compared to $0.16 for the fourth quarter 2018.
Revenue by Geographic Location
Forward Guidance
For the full year 2020, the Company expects to report revenue of $46.3 million to $47.1 million, GAAP diluted earnings per share of $0.72 to $0.80 and non-GAAP diluted earnings per share of $0.84 to $0.92. For the first quarter 2020, the Company expects to report revenue of $10.5 million to $10.7 million, GAAP diluted earnings per share of $0.16 to $0.18 and non-GAAP diluted earnings per share of $0.19 to $0.21.
Challenges Ahead
- The Company expects a higher effective tax rate during the full-year 2020, which negatively impacts forecasted 2020 earnings.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...